tuneTypical Dose
Match only to a studied propolis extract or mouthwash formulation
Supplement
Propolis
Bee resin mixture
Evidence TierCWADA NOT PROHIBITED
watchEffect Window
The main supported indications are short term.
check_circleCompliance
WADA NOT PROHIBITED
Overview
Clinical Summary
Propolis has some real human evidence in upper-respiratory symptom support, oral mucositis, and topical herpes healing, but the evidence is formulation specific and much narrower than broad immune-marketing claims.
Propolis is one of the bee products with some real clinical evidence, but it is still easy to overstate. The clearer human lanes are symptomatic support in uncomplicated upper-respiratory infections, topical support in oral mucositis settings, and now a newer pooled signal for topical herpes-lesion healing. Those are useful but highly product and route specific. They do not justify broad “immune booster” claims for every propolis product.
Propolis contains polyphenols and other bee-derived compounds with antimicrobial and anti-inflammatory activity, but the useful human evidence is still product specific and indication specific.
Outcomes
What This Is Expected To Influence
Primary Outcomes
- Possible reduction in uncomplicated upper-respiratory symptom burden
Secondary Outcomes
- Supportive benefit in oral mucositis settings
Safety
Contraindications and Interactions
Contraindications
- Bee-product allergy
Side effects
- Allergic irritation
Interactions
No entries provided
Avoid if
- You have a known bee-product allergy
- You are expecting broad systemic immune effects from an unstandardized product
Evidence
Study-level References
pro-SRC-001Randomized controlled trial
Sourceopen_in_newCohen HA, et al. A standardized polyphenol mixture extracted from poplar-type propolis for remission of symptoms of uncomplicated upper respiratory tract infection (URTI): A monocentric, randomized, double-blind, placebo-controlled clinical trial. Complement Ther Med. 2020;53:102511. doi:10.1016/j.ctim.2020.102511. PMID:33091857.
Population: Healthy adults with mild uncomplicated upper respiratory tract infection symptoms.
Dose protocol: Standardized poplar-type propolis extract for short-term URTI support
Key findings: Faster symptom remission than placebo in uncomplicated URTI.
Notes: Best direct oral-use anchor.
Paper content
This is one of the better direct propolis trials. It supports a possible symptomatic benefit in uncomplicated URTI, but the finding is formulation specific and should not become a broad immune-boost claim.
pro-SRC-002Randomized controlled trial
Sourceopen_in_newArena AC, et al. Randomized DoubleBlind PlaceboControlled Trial of Propolis for Oral Mucositis in Patients Receiving Chemotherapy for Head and Neck Cancer. Cancer Nurs. 2017. doi:10.1097/CCO.0000000000000316. PMID:27510017.
Population: Patients receiving chemotherapy for head and neck cancer.
Dose protocol: Product-specific propolis mouthwash
Key findings: Reduced oral mucositis severity versus placebo.
Notes: Better-supported topical lane.
Paper content
This trial supports a real mucositis-prevention lane for topical propolis. It is a better-supported niche use than the broad wellness claims often attached to oral propolis supplements.
pro-SRC-003Randomized, double-blind, placebo-controlled trial.
Sourceopen_in_newAfsharpour F, Javadi M, Hashemipour S, Koushan Y, Haghighian HK. Propolis supplementation improves glycemic and antioxidant status in patients with type 2 diabetes. Complement Ther Med. 2019;43:283-288. doi:10.1016/j.ctim.2019.03.001. PMID:30935545.
Population: Adults aged 30 to 55 years with type 2 diabetes.
Dose protocol: Propolis 1500 mg/day for 8 weeks in type 2 diabetes patients
Key findings: Significant reductions in fasting blood sugar, HbA1c, insulin resistance, and improved antioxidant status versus placebo.
Notes: Adds a metabolic and glycemic benefit lane for propolis in T2D. Modest sample (n=62) but well-controlled.
Paper content
This double-blind placebo-controlled trial tested 1500 mg/day propolis for 8 weeks in 62 adults with type 2 diabetes. The propolis group showed significant reductions in fasting blood sugar, postprandial glucose, insulin, insulin resistance, and HbA1c compared to placebo. Antioxidant markers also improved. The trial supports a metabolic benefit lane for propolis supplementation in T2D, though the sample is modest and replication is needed.
pro-SRC-004Systematic review and meta-analysis
Sourceopen_in_newNiode NJ, Christopher PM, Tallei TE. Superiority of propolis and honey over topical acyclovir for herpes simplex: A meta-analysis. Int J STD AIDS. 2026;37(5):511-521. doi:10.1177/09564624251413431. PMID:41496519.
Population: Human studies comparing topical propolis and/or honey against 5% acyclovir for labial or genital herpes lesions.
Dose protocol: Topical propolis and/or honey versus 5% acyclovir across 7 pooled herpes studies
Key findings: Faster lesion healing, higher day-7 healing rates, and shorter pain duration than acyclovir, with no clear adverse-event penalty.
Notes: Topical mixed-formulation evidence only. Useful niche antiviral-support lane, not a general propolis class claim.
Paper content
This 2026 meta-analysis evaluated seven human studies comparing topical propolis and/or honey with 5% acyclovir for labial and genital herpes lesions. The pooled results favored the natural-product arms for faster lesion resolution, higher healing rates by day 7, shorter pain duration, and lower pain intensity, with no clear adverse-event penalty. The main limitation for supplement interpretation is that the pooled intervention mixes propolis with honey and focuses on topical formulations rather than oral supplementation. It still adds a credible, product-specific topical antiviral-support lane for propolis, but it should not be generalized into broad systemic antiviral claims.